Senseonics Announces FDA Approval for a Non-Adjunctive Indication (Dosing Claim) for the Eversense® 90-day CGM System
Senseonics Holdings, Inc. (SENS)
Last senseonics holdings, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
senseonics.com/investor-relations
Company Research
Source: Business Wire
With a non-adjunctive claim, Eversense users will soon be able to manage their diabetes dosing decisions without confirming with fingersticks GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that they received FDA approval for the non-adjunctive indication (dosing claim) for the Eversense Continuous Glucose Monitoring System. Patients will soon be able to use Eversense as a replacement for fingersticks to make diabetes treatment decisions throughout the day. To use the non-adjunctive dosing indication, users will have to download a new app which will be available in coming months. “Receiving the non-adjunctive indication from the FDA marks a major milestone for Senseonics. The Ever
Show less
Read more
Impact Snapshot
Event Time:
SENS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SENS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SENS alerts
High impacting Senseonics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
SENS
News
- Senseonics Holdings, Inc. (NYSE: SENS) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- SAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMSPR Newswire
- Thinking about buying stock in Senseonics Holdings, Ainos, Marpai, Rush Street Interactive, or Evgo?PR Newswire
- Senseonics Holdings, Inc. Announces Data From the Eversense® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes [Yahoo! Finance]Yahoo! Finance
- Senseonics Holdings, Inc. Announces Data From the Eversense® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for DiabetesBusiness Wire
SENS
Earnings
- 2/29/24 - Beat
SENS
Sec Filings
- 4/12/24 - Form ARS
- 4/12/24 - Form DEFA14A
- 4/12/24 - Form DEF
- SENS's page on the SEC website